Basra Mahi, Patel Hemangi, Biglione Alejandro
Osteopathic Medicine, Nova Southeastern University Dr. Kiran C. Patel College of Osteopathic Medicine, Clearwater, USA.
Sports Medicine, Nova Southeastern University Dr. Kiran C. Patel College of Osteopathic Medicine, Fort Lauderdale, USA.
Cureus. 2024 Apr 23;16(4):e58846. doi: 10.7759/cureus.58846. eCollection 2024 Apr.
Breast cancer is a common malignancy in women, and the survival rate for this cancer is low once it metastasized. Currently, chemotherapy is the first-line treatment for metastatic breast cancer (MBC). However, when liver metastases (LM) are present, the response to chemotherapy is poor. Regional intra-arterial chemotherapy (RIAC) delivers a high concentration of anticancer drugs to the malignant tissue, which improves the survival rate of patients with LM. It also decreases systemic side effects associated with chemotherapy. RIAC leads to higher remission rates because it directly targets the affected area. When RIAC is used alongside systemic chemotherapy, tumor resistance is decreased, increasing the rates of remission. This review aims to introduce the use of RIAC in patients with MBC. RIAC is a relatively new therapy in interventional oncology, and thus, limited research is currently available.
乳腺癌是女性常见的恶性肿瘤，一旦发生转移，该癌症的生存率较低。目前，化疗是转移性乳腺癌（MBC）的一线治疗方法。然而，当存在肝转移（LM）时，化疗反应较差。区域动脉内化疗（RIAC）可将高浓度的抗癌药物输送到恶性组织，从而提高LM患者的生存率。它还可减少与化疗相关的全身副作用。RIAC直接靶向受影响区域，因此缓解率更高。当RIAC与全身化疗联合使用时，肿瘤耐药性降低，缓解率增加。本综述旨在介绍RIAC在MBC患者中的应用。RIAC是介入肿瘤学中一种相对较新的治疗方法，因此目前可用的研究有限。
